Trial Profile

A Phase 1, single-center, multiple-dose, open-label sequential study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of methadone or buprenorphine/naloxone when coadministered with Glecaprevir (ABT-493) + Pibrentasvir (ABT-530) in HCV-negative subjects on opioid maintenance therapy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary) ; Buprenorphine/naloxone; Methadone
Indications Opioid-related disorders
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

14 Aug 2017 Results assessing the safety, tolerability, pharmacodynamics and pharmacokinetics of methadone or buprenorphine/naloxone when coadministered with Glecaprevir (ABT-493) + Pibrentasvir (ABT-530) in HCV-negative subjects on opioid maintenance therapy were published in the Antimicrobial Agents and Chemotherapy
11 Mar 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com